Janus Henderson Group PLC Raises Position in Geron Corporation $GERN

Key Points

• Janus Henderson Group increased its Geron position by 826.7% in the first quarter, adding 1.98 million shares to hold 2.22 million shares worth approximately $3.3 million.
• Institutional ownership of Geron stands at 73.71%, with several other investment firms also initiating or expanding positions.
• Geron reported record quarterly revenue of $57.48 million, ahead of estimates, but missed on EPS with a $0.02 loss per share. Analyst sentiment remains mixed, with a consensus “Hold” rating and a $4.00 price target.

Janus Henderson Group PLC raised its holdings in shares of Geron Corporation (NASDAQ:GERN - Free Report) by 826.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,218,196 shares of the biopharmaceutical company's stock after buying an additional 1,978,839 shares during the quarter. Janus Henderson Group PLC owned about 0.35% of Geron worth $3,304,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. 55 North Private Wealth LLC bought a new stake in shares of Geron during the 4th quarter valued at about $29,000. LCM Capital Management Inc raised its stake in Geron by 80.6% in the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 10,000 shares in the last quarter. Vistica Wealth Advisors LLC bought a new stake in Geron during the fourth quarter valued at approximately $33,000. Hsbc Holdings PLC bought a new stake in Geron during the first quarter valued at approximately $33,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in Geron by 3,307.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 24,410 shares in the last quarter. 73.71% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Geron from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, July 24th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $4.00.

Geron News Roundup

Here are the key news stories impacting Geron this week:

• Positive Sentiment: Geron reported record second-quarter revenue of $57.48 million, exceeding the $55.30 million analyst consensus, with growth attributed to demand for Rytelo. The revenue beat supports the commercial potential of the company’s lead product. Geron adds a record 16% as Rytelo drives Q2 revenue beat
• Positive Sentiment: Traders purchased a large volume of Geron call options, signaling that some market participants are positioning for potential upside in GERN. However, options activity does not guarantee a sustained move in the stock. Stock Traders Buy Large Volume of Geron Call Options
• Neutral Sentiment: Analyst opinions on Geron remain mixed, indicating uncertainty about the company’s earnings trajectory and the pace at which Rytelo can translate into profitability. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Negative Sentiment: Geron reported a second-quarter loss of $0.02 per share, missing the $0.01-per-share loss analysts expected. Its negative net margin and continued losses highlight that the company has not yet achieved profitability. Geron: Q2 Earnings Snapshot
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across 2026 through 2030, including estimates of a $0.05 loss for 2026, $0.02 EPS for 2027, $0.12 for 2028, $0.32 for 2029 and $0.55 for 2030. The revisions suggest weaker near- and long-term earnings expectations, likely contributing to selling pressure. HC Wainwright Geron EPS Estimates

Geron Trading Down 5.7%

Shares of GERN stock opened at $1.48 on Friday. The business has a 50-day moving average price of $1.34 and a two-hundred day moving average price of $1.46. Geron Corporation has a 12-month low of $1.04 and a 12-month high of $2.01. The company has a quick ratio of 4.96, a current ratio of 6.91 and a debt-to-equity ratio of 0.55. The firm has a market cap of $950.86 million, a P/E ratio of -13.45 and a beta of 0.61.

Geron (NASDAQ:GERN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The firm had revenue of $57.48 million for the quarter, compared to the consensus estimate of $55.30 million. Geron had a negative net margin of 34.17% and a negative return on equity of 24.48%. Equities analysts anticipate that Geron Corporation will post -0.04 EPS for the current fiscal year.

Geron Profile

Geron Corporation NASDAQ: GERN is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company's research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source